pacemaker

¿Cómo clasificar la estenosis aórtica de los pacientes que recibieron TAVI?

More Favorable Evidence for TAVR in Severe Aortic Regurgitation

Courtesy of Dr. Carlos Fava. Transcatheter aortic valve replacement (TAVR) was developed for aortic stenosis, but there is a significant number of patients with severe aortic regurgitation who still undergo this procedure as an off-label indication. Current evidence for this procedure in relation with this disease is growing, mainly due to good results obtained by different<a href="https://solaci.org/en/2018/07/27/more-favorable-evidence-for-tavr-in-severe-aortic-regurgitation/" title="Read more" >...</a>

MitraClip frecuencia ritmo cardíaco

MitraClip in Severe MR: 5 Year Mortality Rate Similar to Surgery

Courtesy of Dr. Carlos Fava. Mitral regurgitation accounts for around 25% of valvular diseases and is a strong mortality predictor in heart disease. One of the challenges of this disease is that patients respond favorably to medical treatment for a long time, which makes hard to establish the right time to perform an intervention without<a href="https://solaci.org/en/2018/07/05/mitraclip-in-severe-mr-5-year-mortality-rate-similar-to-surgery/" title="Read more" >...</a>

Urgent/Emergent TAVR: A Valid Option

Courtesy of Dr. Carlos Fava. Aortic stenosis with cardiac failure or cardiogenic shock involves high mortality risk at short term. Surgery in these conditions is often unsafe, which leaves us with valvuloplasty, but only as a bridge to some other procedure, seeing as it is effective only for a short time. Few studies have looked into patients undergoing<a href="https://solaci.org/en/2018/06/20/urgent-emergent-tavr-a-valid-option/" title="Read more" >...</a>

The Largest Registry on the ACURATE neo Valve

Transcatheter aortic valve replacement (TAVR) using the ACURATE neo device depends, largely, on correct patient selection and appropriate oversizing. The individual anatomy of each patient, namely periannular and aortic root calcification, must be taken into account. The ACURATE neo valve (Symetis/Boston, Ecublens, Switzerland) is a new-generation self-expanding valve characterized by a stent design shaped as an X<a href="https://solaci.org/en/2018/06/15/the-largest-registry-on-the-acurate-neo-valve/" title="Read more" >...</a>

¿Es durable el TAVI a más de 5 años?

Is TAVR Durable Beyond 5 Years?

Courtesy of Dr. Carlos Fava. The benefits derived from transcatheter aortic valve replacement (TAVR) are clear and self-evident, and its progressively better outcomes are due to better patient selection, greater operator experience, and the development of new valves that enhance procedural safety and complexity. However, the question of durability remains a major unresolved issue, particularly now<a href="https://solaci.org/en/2018/05/22/is-tavr-durable-beyond-5-years/" title="Read more" >...</a>

Se publicaron los resultados del estudio RESPECT con excelentes novedades

Liver Failure as a Challenge for TAVR

Although surgical risk scores do not include liver failure (LF), patients who suffer from it and undergo cardiovascular surgery present high rates of morbidity and mortality. This is due to alteration of cardiac function, increased infection susceptibility, gastrointestinal complications, and increased bleeding. As regards transcatheter aortic valve replacement (TAVR), these patients have not been included<a href="https://solaci.org/en/2018/05/03/liver-failure-as-a-challenge-for-tavr/" title="Read more" >...</a>

La cirugía parece superior a la angioplastia en pacientes jóvenes

TAVR with Prior MRS: A New Challenge

The benefits of transcatheter aortic valve replacement (TAVR) for high-risk, prohibitive-risk (class I) or intermediate-risk (class IIa) patients have already been proven, but there is a growing population of patients with a history of myocardial revascularization surgery (MRS) who experience severe aortic stenosis. Decision-making in these cases is anything but simple, mainly due to the presence of<a href="https://solaci.org/en/2018/05/02/tavr-with-prior-mrs-a-new-challenge/" title="Read more" >...</a>

TAVI-compressor

Bicuspid Valves Do Not Increase Mortality in TAVR

The frequency of bicuspid aortic valves (BcAV) are around 1%, but in 60+ patients it is associated to severe aortic stenosis. Even though surgery is the standard treatment, TAVR is the “off label” indication in high risk patients. &nbsp; BcAV presents differences with tricuspids given that it is more elliptic, has asymmetric calcification and more<a href="https://solaci.org/en/2018/05/02/bicuspid-valves-do-not-increase-mortality-in-tavr/" title="Read more" >...</a>

Transcatheter Valve Replacement in the Bicuspid Valve Is Increasingly Performed, but Challenges Remain

Delayed Coronary Obstruction After TAVR: A Complication We Had Not Considered

Delayed coronary obstruction (after TAVR, outside the cath lab) is a rare complication with high mortality rates, not unlike acute obstruction. Cardiologists should be expectant and, upon the slightest suspicion of this complication, patients should be brought back to the cath lab for a coronary angiography. Occlusion immediately after implant release has been well-studied and<a href="https://solaci.org/en/2018/04/11/delayed-coronary-obstruction-after-tavr-a-complication-we-had-not-considered/" title="Read more" >...</a>

Remodelado miocárdico reverso luego del reemplazo valvular

Reverse Myocardial Remodeling Following Valve Replacement

After aortic valve replacement, focal fibrosis does not resolve, but diffuse fibrosis and cell hypertrophy regress. As expected, this regression comes with structural and functional improvement that suggest it is a dynamic process. Fibrosis can be measured and quantified with cardiovascular MR, which makes it a potential therapeutic objective. Left ventricular hypertrophy is a key<a href="https://solaci.org/en/2018/04/08/reverse-myocardial-remodeling-following-valve-replacement/" title="Read more" >...</a>

Top